Key clinical point: Adding daratumumab to bortezomib, lenalidomide, and dexamethasone (RVd) improved responses in transplant-eligible patients with newly diagnosed multiple myeloma.
Major finding: Stringent complete response by the end of consolidation was achieved by 42.4% of patients in the daratumumab-RVd arm and 32.0% in the RVd arm (odds ratio = 1.57; P = .068). The overall response rate was 99.0% and 91.8%, respectively (P = .0160).
Study details: A phase 2 trial of 207 patients with transplant-eligible, newly diagnosed multiple myeloma.
Disclosures: The speaker reported relationships with Janssen, which sponsored the trial, and several other companies.
Voorhees PM et al. IMW 2019, Abstract OAB-087.